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Aims Genome-wide association studies revealed an association between a locus at 10q11, downstream from CXCL12, and
myocardial infarction (MI). However, the relationship among plasma CXCL12, cardiovascular disease (CVD) risk
factors, incident MI, and death is unknown.
Methods
and results
We analysed study-entry plasma CXCL12 levels in 3687 participants of the Chronic Renal Insufficiency Cohort (CRIC)
Study, a prospective study of cardiovascular and kidneyoutcomes in chronic kidney disease (CKD) patients. Mean follow-
up was 6 years for incident MI or death. Plasma CXCL12 levels were positively associated with several cardiovascular risk
factors (age, hypertension, diabetes, hypercholesterolaemia), lower estimated glomerular filtration rate (eGFR), and
higher inflammatory cytokine levels (P , 0.05). In fully adjusted models, higher study-entry CXCL12 was associated
with increased odds of prevalent CVD (OR 1.23; 95% confidence interval 1.14, 1.33, P , 0.001) for one standard devi-
ation (SD) increase in CXCL12. Similarly, one SD higher CXCL12 increased the hazard of incident MI (1.26; 1.09,1.45,
P , 0.001), death (1.20; 1.09,1.33, P , 0.001), and combined MI/death (1.23; 1.13–1.34, P , 0.001) adjusting for demo-
graphic factors, known CVD risk factors, and inflammatory markers and remained significant for MI (1.19; 1.03,1.39,
P ¼ 0.01) and the combined MI/death (1.13; 1.03,1.24, P ¼ 0.01) after further controlling for eGFR and urinary
albumin:creatinine ratio.
Conclusions In CKD, higher plasma CXCL12 was associated with CVD risk factors and prevalent CVD as well as the hazard of incident
MI and death. Further studies are required to establish if plasma CXCL12 reflect causal actions at the vessel wall and is a
tool for genomic and therapeutic trials.
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Despite considerable advances in treatment and understanding of
cardiovascular diseases (CVD), there is still substantial residual
risk for cardiovascular events even after optimal management of
known risk factors.1 This observation supports the need to discover
novel pathways in CVD and to identify causal biomarkers to leverage
opportunities for novel therapeutic targeting. Modern genomics,
particularly genome-wide association studies (GWAS), have
revealed a substantial list of potentially causal genes and pathways
for CVD, although most remain largely unexplored.2 –5 One such
example is the chemokine ‘CXC Motif, Ligand 12’ (CXCL12), which
encodes an inflammatory chemokine expressed in cells of relevance
to CVD.6 A particular distinction of this locus is that CXCL12 has a
measureable gene product circulating in blood.7 In several GWAS,
the CXCL12 region was identified as a locus for myocardial infarction
(MI),2– 5 and single-nucleotide polymorphisms (SNPs) at this region
appear to modulate plasma CXCL12 levels although findings
on plasma CXCL12 are conflicting.8,9 There are several isoforms
of the human CXCL12 protein, also called stromal-derived factor
(SDF)-1, expressed in a tissue-specific manner adding to the com-
plexity of studying CXCL12 biology.10 CXCL12 is a complex
chemokine with putative anti-inflammatory and anti-atherogenic
functions that also plays a role acutely in recruiting EPCs in response
to vascular injuries. CXCL12 is highly expressed in human athero-
sclerotic plaque within endothelial cells (ECs) and smooth muscle
cells (SMCs).6 The protein products of the gene CXCL12 are alterna-
tive spliced variants and the common isoforms, often called SDF 1a
and SDF 1b, are coded from 3 exons and 4 exons, respectively.7
CXCL12hasbeen implicated inhaematopoiesis, stemcellmobilization
from the bone marrow (BM), and angiogenesis,11 and these functions
contribute to its homeostatic functions and response to injuries. There
are two receptors for CXCL12, CXCR4, and CXCR7. CXCR4 has
been implicated in recruitment of atherogenic cells, including macro-
phages and SMCs,12 to the neo-intima. These biological observations
suggest an important role for CXCL12 in human vascular disease.
Clinical data for CXCL12 in human atherosclerotic CVD are
sparse. In one small study, Damas et al.13 reported that plasma
levels of CXCL12 were decreased in symptomatic CAD cases com-
pared with controls and, in particular, levels were lowest in patients
with acute coronary syndromes. They found also that CXCL12 treat-
ment reduced ex vivoproduction of inflammatory atherogenic signals,
MCP-1, IL-8, and MMPs, in peripheral blood mononuclear cells
(PBMCs). These results may suggest anti-inflammatory and plaque
stabilization functions of CXCL12 in atherosclerosis. Kiechl et al.9
found that rs501120, an MI-related SNP in the CXCL12 region, was
associated with greater carotid intimal-medial thickness (IMT) and
lower plasma CXCL12 levels, whereas we have demonstrated that
the same MI risk alleles were related to higher plasma CXCL12
levels.8 To date, mouse models have failed to resolve the vascular
biology of Cxcl12 in part due to the distinct receptors and signalling
pathways, lethality of germline gene deficiencies, and differences in
vascular model employed and phenotypes examined.14 –16
Patients with chronic kidney disease (CKD) are at high risk
for CVD in part due to a pro-inflammatory milieu characterized by
increases in circulating cytokines and chemokines.17 The Chronic
Renal Insufficiency Cohort (CRIC) study is a multi-centre, prospect-
ive cohort study designed to examine risk factors for progressive
CKD and CVD.18 We focused on this unique clinical population at
increased risk of CVD for measurement of plasma CXCL12
to better understand the relationship of this GWAS locus with
cross-sectional data and incident CVD events. Using data from the
CRIC study, we performed the first prospective study of plasma
CXCL12 levels with subsequent clinical outcomes and hypothesized
that higher plasma CXCL12 levels at study entry would be associated
with increased rates of MI and death.
Methods
Study population
The CRICstudy is anongoingNational Institute ofHealth (NIH),National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-
sponsored, prospective, observational cohort study of CKD. Participants
were recruited across seven study sites in the USA between 2003 and
200618,19 and additional Hispanic participants were recruited from one
site between 2005 and 2008, as the ancillary Hispanic CRIC.20 The base-
line characteristics of the CRIC cohort have been reported.19 Briefly, the
CRIC study recruited 3939 individuals between 2003 and 2008 and the
cohort has been followed with annual in-person visits since recruitment.
Subjects were aged 21–74 years, 46% female, and were recruited to be
racially and ethnically diverse (45% white, 46% black, 5% Hispanic, 4%
Asian/Pacific Islander/Native American), to have a broad spectrum of
renal disease severity [estimated glomerular filtration rate (eGFR)
15–90; mean 43.4+13.5 mL/min] with 50% having diabetes melli-
tus. To limit the proportion of older individuals who were recruited
with age-related diminutions of GFR but otherwise non-progressive
CKD, age-based eGFR entry criteria were used. Participants were
excluded if unable to provide written informed consent, institutionalized,
enrolled in other studies, pregnant, had New York Heart Association
class III to IV heart failure, human immunodeficiency virus infection, cir-
rhosis, myeloma, polycystic kidney disease, renal cancer, recent chemo-
therapy or immunosuppressive therapy, organ transplant, or had prior
treatment with dialysis for at least 1 month.18 The CRIC study protocol
was approved by the Institutional Review Boards (IRB) of all participating
institutions (Ann Arbor, Michigan; Baltimore, Maryland; Chicago, Illinois;
Cleveland, Ohio; New Orleans, Louisiana; Philadelphia, Pennsylvania;
and Oakland, California) and study participants provided written
informed consent. The CRIC study has extensive data management
protocols with security and privacy checks18 overseen by the CRIC
study Coordinating Centre, based at the University of Pennsylvania.
The study complies with the Declaration of Helsinki.
Exposures and outcomes
The primary exposure was plasma CXCL12, measured in samples
at study entry in 3869 of the 3939 participants. Due to missing values
for body mass index (BMI) (n ¼ 10), interleukin-6 (IL6) and tumour ne-
crosis factor-alpha (TNFa) (n ¼ 37), and for urinary albumin:creatinine
ratio (n ¼ 135), the final sample for analysis consisted of 3687 CRIC par-
ticipants. The 252 excluded participants differed slightly from included
subjects in age (58 vs. 60 years; P , 0.001) and racial/ethnic distribution
(White29%vs. 42%,Black51% vs. 41%,Hispanic17%vs. 12%;P , 0.001),
but otherwise had no statistically significant differences in cardiovascular
and kidney parameters.
CXCL12 levels were measured in previously unthawed plasma samples
using a commercial ELISA [Quantikine Immunoassay (R+D Systems,










Minneapolis, MN, USA)].8,13 Blood samples were spun within an hour of
collection at 1000 g at 48C, and EDTA plasma frozen at 2808C. Aliquots
were thawed and spun at 10 000 g for 15 min at 48C prior to performing
the CXCL12 ELISA. Samples were run in duplicate, averaged, and the
intra- and inter-assay coefficients of variation were 4.2 and 13.8%, respect-
ively. The specificity of this assay using western blotting and recombinant
proteins confirms that the predominant isoform, isoform-alpha, but not
the beta isoform, is detected (communication Chris Larson, R+D).10 As
described,17 high-sensitivity plasma C reactive protein (hsCRP) was
assayed by nephelometry and levels of IL6 and TNFa were measured by
high-sensitivity ELISA (R+D Systems).
Demographic factors and clinical data were obtained at baseline and
annually by interview and questionnaire. Additional blood and urine
laboratory tests were measured centrally using standard assays. Lipids
including total, high- and low-density cholesterol, as well as triglycerides
were measured enzymatically (Hitachi 912, Roche Diagnostic Systems,
Inc., NJ, USA). We used a CRIC-specific equation (including serum cre-
atinine, cystatin C, age, sex, and race) for estimating glomerular filtration
rate (eGFR) based on iothalamate GFR measurements as described.21
Diabetes mellitus was defined as fasting glucose ≥126 mg/dL, random
glucose ≥200 mg/dL, or use of insulin or anti-diabetic medication.
Participants had three seated blood pressures recorded at each visit,
as previously described.18 Hypertension was defined as a systolic BP
≥140 mmHg, diastolic BP ≥90 mmHg, or use of antihypertensive med-
ications. Hypercholesterolaemia was defined as the use of cholesterol-
lowering medications or total serum cholesterol .200 mg/dL.
The primary outcomes were incident MI, all-cause death, and a
composite of these endpoints. Incident MI was defined by review of
hospitalization records and participant interviews. Participants were
asked at each contact if they had been hospitalized, and if so, records
were obtained if the billing codes included pre-defined MI codes.
Records were reviewed by two physician adjudicators for cardiac bio-
marker data, including troponin and creatine kinase, electrocardiograms
(ECGs), and symptoms of angina. The classification of an event as a def-
inite, probable, or not an MI was made by each physician separately based
on independent review of data and the final adjudication required the
agreement of the two physician reviewers. All-cause death was con-
firmed by report from next of kin, a review of hospital records if death
occurred in hospital or via the social security death index. Participants
were followed at annual visits and interim telephone calls until occur-
rence of death, withdrawal from the study, loss to follow-up, or
30 June 2009 when data were locked for this analysis. More than 90%
of the participants were retained during the longitudinal observation
period through 2009.
Prevalent CVD at enrolment [defined as self-reported prior diagnosis
of coronary heart disease (CHD), stroke or peripheral vascular disease]
was analysed as a secondary outcome.
Statistical analysis
One-way analysis of variance (continuous variables) and Pearson’s x2
tests (categorical variables) were used to compare clinical characteristics
across baseline quartiles of plasma CXCL12 levels. We used logistic re-
gression to examine unadjusted and multivariable-adjusted relationships
between plasma CXCL12 level and prevalent CVD at enrolment.
CXCL12 values were standardized by subtracting the sample mean and
dividing by the standard deviation (SD). Odds ratios (ORs) are reported
per one SD increment of standardized CXCL12. Becausewe lacked prior
evidence of linear associations of CXCL12 with outcomes, we also
report ORs for above the median plasma CXCL12 value (median is
2.432 ng/mL). Incremental models were fitted adjusting for: (Model 1)
demographic factors (age, sex, and race); (Model 2) demographic and
traditional CVD risk factors (BMI and binary indicators for diabetes,
hypertension, hypercholesterolaemia, and tobacco use); (Model 3)
demographic, traditional risk factors, and inflammatory biomarkers (log-
transformed IL6, TNFa, and high-sensitivity C reactive protein levels);
and (Model 4) demographic, traditional risk factors, inflammatory bio-
markers, and measures of kidney function (CRIC-defined eGFR and
urinary albumin:creatinine ratio). Cox proportional hazards regression
was used to examine unadjusted and multivariable-adjusted relationships
between CXCL12, per 1 SD increment of standardized CXCL12 and for
above the median plasma CXCL12, and each of the following incident
endpoints: (1) probable MI, (2) definite MI, (3) death, and (4) a composite
outcome of MI and death (MI/death). A similar modelling approach was
applied as outlined above with adjustment for additional factors as
detailed in results. Kaplan–Meier plots were generated using quartiles
of CXCL12 data to illustrate findings. The impact of plasma CXCL12
on the prognostic performance in risk prediction models was examined
with change in the area under the curve (AUC) forprobableMI, deathand
their combined outcome using approaches described by Pencina et al.,22
and then using the Net Reclassification Index (NRI) from simple cross-
tabulation of 10-year risk categories (e.g. ‘low risk’ 0%–10%, ‘medium
risk’ 10%–20%, ‘high risk’ .20%) based on predicted probabilities
obtained using models with and without CXCL12 (included as a continu-
ous variable).22,23 Analyses were performed using the R platform for stat-
istical computing, version 2.15.2. AUC in receiver operator curve (ROC)
analysis is performed using the concordance.index() and cindex.comp()
functions in the survcomp package in R version3.0.1., and the NRI analysis
was performed using the nricens () function in the nricens package in
R version. All statistical tests were 2-sided, and P values , 0.05 were
considered statistically significant.
Results
Association of plasma CXCL12 levels
with demographic and clinical factors
The distribution of plasma levels of CXCL12 in the full cohort is
shown in Figure 1. Baseline characteristics of study participants by
CXCL12 quartiles are presented in Table 1 and Supplementary ma-
terial online, Table S1. There were significant associations of higher
plasma CXCL12 with increasing age, Black and Hispanic race/ethni-
city, prior CVD, diabetes, hypertension, hypercholesterolaemia,
BMI, and plasma levels of inflammatory markers IL6, TNFa, and high-
sensitivity C reactive protein. Reduced kidney function, estimated by
lower eGFR, higher plasma cystatin C, and higher urinary albumin:-
creatinine ratio were also associated with higher CXCL12.
Plasma CXCL12 and prevalent
cardiovascular disease
Our primary focus was to understand the effect of plasma CXCL12
on incident events. First, however, we analysed cross-sectional asso-
ciations to understand how plasma CXCL12 levels at enrolment
related to prevalent CVD and its risk factors. Study entry CXCL12
levels, whether considered as a 1 SD increase in standardized
CXCL12 or greater than the median CXCL12, were associated
with higher prevalence of CVD in models adjusting for demographic
factors, known CVD risk factors, and inflammatory biomarkers (IL6,
TNFa, and high-sensitivity C reactive protein) (OR 1.30; P , 0.001
and OR 1.53; P , 0.001, respectively) and after controlling further
for study entry eGFR and urinary albumin:creatinine ratio (OR
1.23; P , 0.001 and OR 1.38; P , 0.001, respectively) (Table 2).










Plasma CXCL12 and occurrence
of myocardial infarction and death
During a median follow-up of 6 years, a total of 174 participants
experienced a probable MI; of these participants, 127 experienced
a definite MI. A total of 355 participants died and 485 experienced
the composite outcome of MI or death. Compared with those
without the respective event, median CXCL12 levels were signifi-
cantly higher in those who had probable MI [2.63 ng/mL; IQR (2.29,
2.96) vs. 2.42 ng/mL (2.07, 2.81)], definite MI [2.63 ng/mL (2.30,
2.95) vs. 2.42 ng/mL (2.07, 2.81)], died [2.63 ng/mL (2.26, 3.09) vs.
2.41 ng/mL (2.06, 2.79)] or experienced the composite of MI/death
[2.63 ng/mL (2.26, 3.03) vs. 2.41 ng/mL (2.06, 2.79)].
Table 3 presents multivariable-adjusted hazard ratios (HRs) for
probable MI, death, or the composite of MI/death according to
1 SD increase in the standardized CXCL12 and for those with above-
median plasma CXCL12. Study entry CXCL12 levels predicted MI
(HR 1.26; P ¼ 0.001), death (HR 1.20; P , 0.001), and the combined
event (HR 1.23; P , 0.001) in models adjusted for demographic
factors, known risk factors, and inflammatory biomarkers (IL6,
TNFa, and high-sensitivity C reactive protein) and remained signifi-
cant for MI (1.19; P ¼ 0.01) and the composite of MI/death (1.13;
P ¼ 0.01) outcomes after further adjusting for study entry eGFR
and urinary albumin:creatinine ratio (Table 3). Analyses of CXCL12
levels above the median had similar patterns (e.g. in fully adjusted
models HR for probable MI 1.52; P , 0.001, HR for death 1.28;
P ¼ 0.03, HR for composite of MI/death 1.30; P ¼ 0.008) (Table 3).
Further adjustment for prevalent CVD slightly attenuated the esti-
mates for incident events (HR for MI 1.43; P ¼ 0.034; HR for death
1.21, P ¼ 0.097; HR for composite of MI/death 1.23, P ¼ 0.033).
Kaplan–Meier plots for age, gender, and race adjusted as well as
fully adjusted associations between quartiles of plasma CXCL12
and probable MI, death, or composite of MI/death are shown in
Figure 2.
When using the more stringent outcome definition of definite MI,
similar effect estimates as those for probable MI were observed (Sup-
plementarymaterial online,Table S2); however, statistical significance
was slightly attenuated, likely due to the smaller number of events
(127 definite MIs vs. 174 probable MIs). The HR for definite MI was
1.14, CI 0.95, 1.36, P ¼ 0.16 in adjusted model (demographics, CV
risk factors, inflammatory biomarkers, eGFR, urinary albumin:creati-
nine ratio) for 1 SD increase in standardized plasma CXCL12 and
1.53, CI 1.04–2.25, P ¼ 0.03 in the same adjusted model for values
above the median CXCL12.
Finally, we evaluated the AUC and the NRI in order to explore the
predictive performance of plasma CXCL12 when added to tradition-
al and novel risk factors. Change in AUC for probable MI, death, and
their combined outcome was evaluated in incrementally adjusted
models (Table 4). Plasma CXCL12 significantly improved the AUC
when added to demographic and traditional risk factor for all three
outcomes and modestly increased the AUC for all outcomes when
added to demographic factors, known risk factors and eGFR
(Table 4A). In comparison, we found that eGFR significantly improved
the AUC when added to demographic and traditional risk factor for
all three outcomes as well as improving AUCs for all outcomes when
added to demographic factors, known risk factors, and CXCL12
(Table 4B). In reclassification analyses, there was small improvement
in the NRI for probable MI and death when CXCL12 was added to a
model containing traditional risk factors (Supplementary material
online, Table S3).
Discussion
In cross-sectional analyses and the first prospective study of plasma
CXCL12 with longitudinal outcomes, we found that study entry
levels were associated with prevalent CVD as well as incident MI
and death over a 6-year period in a high-risk CKD population. Al-
though plasma CXCL12 levels were associated with measures of
kidney function as well as multiple demographic and CVD risk
factors, significant associations persisted, albeit with some attenu-
ation, even after adjusting for risk factors and measures of kidney
function.
CXCL12 was identified as a potential gene for CHD through
GWAS of MI.4 Most recently, this GWAS locus association with
CHD was confirmed in GWAS meta-analyses of over 100 000 indivi-
duals.2,5 CXCL12 is biologically plausible in CVD as it plays a role in
recruiting leucocytes in response to vascular injuries14 and has been
implicated in atherosclerosis in rodent models.15,16 CXCL12 is also
expressed in human atherosclerosis within endothelial cells and
SMCs.12 Findings, however, are conflicting with respect to the direc-
tion of effect of CXCL12 in human disease perhaps reflecting its
complex biology with six known CXCL12 coding splice variants7,10
and two distinct signalling receptors (CXCR4 and CXCR7)24 as
well as a dearth of prospective clinical data. Twosmall cross-sectional
human studies reported that plasma CXCL12 was altered in human
CAD,13 with lower levels associated with acute MI. It is possible,
Figure 1 Distribution of plasma CXCL12 levels in the study
sample.










however, that plasma CXCL12 levels drop during the acute inflam-
mation of MI. Indeed, we have observed a drop in plasma CXCL12
levels following intravenous lipopolysaccharide administration in
humans (NNM and MPR, unpublished data). A fall in plasma
CXCL12 during inflammatory stress could reflect active signalling
and sequestration of CXCL12 at its receptors25,26 confounding inter-
pretation of plasma level measurement in acute MI. Kiechl et al. 9
found in the Bruneck study that increased carotid IMT was associated
with lower plasma CXCL12 levels. In contrast, our group has shown
that the GWAS allele for increased MI was associated with increased
CXCL12 mRNA levels in the liver and natural killer cells, as well as
higher plasma CXCL12 levels, suggesting that this GWAS locus
might increase risk of MI through increased CXCL2 expression.8 Im-
portantly, our new data in stable CKD patients recruited to a
prospective cohort show that higher plasma CXCL12 relate to
future MI and death over a 6-year follow-up.
Animal studies of this pathway are challenging to interpret due to
contrasting effects of Cxcl12 depending on the vascular phenotype,
the acuity of the model, or the receptor pathway studied. For
example, in mice with established atherosclerosis, acute blockade
of Cxcr4, one of the Cxcl12 receptors, accelerated atherosclerosis
with expansion of plaque neutrophils and macrophages suggesting
an anti-atherogenic function for Cxcl12.15 In contrast, atherosclerot-
ic apoE2/2 mice had smaller plaque areas and SMC content after re-
population with Cxcr42/2 bone marrow or transfer of a lentivirus
encoding a Cxcl12-alpha antagonist, suggesting that CXCL12-alpha
might be pro-atherogenic.16 Knockout of Cxcl12 and its receptors
is lethal in mice and studies of conditional deletion in atherosclerosis
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Characteristic (n ¼ 3687) n ¼ 923 n ¼ 922 n ¼ 921 n ¼ 921
Demographics
Age (years) 59 (50, 65) 60 (53, 66) 60 (53, 66) 61 (54, 68) ,0.001
Female sex (n ¼ 1655, 44.9%) 422 (11.5%) 378 (10.3%) 402 (10.9%) 453 (12.3%) ,0.01
Race
White (n ¼ 1564, 42.4%) 423 (27.1%) 417 (26.7%) 369 (23.6%) 355 (22.7%) ,0.001
Black (n ¼ 1521, 41.3%) 365 (24.0%) 375 (24.7%) 388 (25.5%) 393 (25.8%)
Hispanic (n ¼ 455, 12.3%) 86 (18.9%) 94 (20.7%) 128 (28.1%) 147 (32.3%)
Other (n ¼ 147, 4%) 49 (33.3%) 36 (24.5%) 36 (24.5%) 26 (17.7%)
Traditional CV risk factors
Prior CVD (n ¼ 1232, 33.4%) 226 (18.3%) 265 (21.5%) 339 (27.5%) 402 (32.6%) ,0.001
Diabetes (n ¼ 1781, 48.3%) 358 (20.1%) 416 (23.4%) 482 (27.1%) 525 (29.5%) ,0.001
Tobacco use (n ¼ 473, 12.8%) 106 (22.4%) 108 (22.8%) 124 (26.2%) 135 (28.5%) 0.13
Body mass index (kg/m2)a 30.6 (26.9, 35.1) 30.8 (27.0, 35.9) 30.9 (26.8, 36.2) 31.20 (26.8, 37.1) 0.01
Hypertension (n ¼ 3171, 86.0%) 750 (23.7%) 787 (24.8%) 811 (25.6%) 823 (26.0%) ,0.001
Hyperlipidaemia (n ¼ 3034, 82.3%) 732 (24.1%) 754 (24.9%) 769 (25.4%) 779 (25.7%) 0.02
Kidney function measuresa
Estimated GFR (mL/min/1.73 m2) 52.3 (41.3, 64.2) 46.3 (35.8, 58.5) 39.9 (31.1, 51.2) 34.2 (25.6, 44.0) ,0.001
Cystatin C (mg/L) 1.16 (0.95, 1.45) 1.30 (1.07, 1.66) 1.50 (1.20, 1.88) 1.75 (1.42, 2.18) ,0.001
Urinary ACR (mg/mg)* 20.1 (5.6, 217.3) 35.1 (7.2, 344.9) 84.0 (9.8, 622.4) 137.5 (21.1, 842.7) ,0.001
Mineral metabolism parametersa
Serum calcium (mg/dL) 9.2 (8.9, 9.5) 9.2 (8.9, 9.5) 9.2 (8.9, 9.4) 9.2 (8.8, 9.5) 0.27
Serum phosphate level (mg/dL) 3.5 (3.2, 3.9) 3.6 (3.2, 4.0) 3.7 (3.3, 4.2) 3.9 (3.4, 4.3) ,0.001
Fibroblast growth factor 23 (RU/mL) 111 (81, 172) 130 (86, 201) 157 (107, 252) 208 (128, 339) ,0.001
Serum inflammatory biomarkersa
IL6 (pg/mL)* 1.53 (0.93, 2.48) 1.78 (1.07, 2.73) 2.00 (1.26, 3.42) 2.37 (1.49, 3.98) ,.001
TNFa (pg/mL)* 1.80 (1.20, 2.60) 2.00 (1.40, 3.00) 2.30 (1.70, 3.30) 2.80 (2.00, 3.80) ,.001
High-sensitivity C-reactive protein (pg/mL)* 2.37 (1.02, 5.55) 2.58 (1.09, 6.70) 2.58 (1.04, 6.25) 2.71 (1.06, 7.13) 0.03
Values shown as median (IQR) or n (%).
CVD, cardiovascular disease; GFR, glomerular filtration rate; ACR, albumin:creatinine ratio; tobacco use defined as former or current smoker.
P-value by ANOVA (continuous variables; those marked with * were log-transformed to meet normality assumption) and x2 test (categorical variables).
aPresented as median (interquartile range).










have not yet been published. Thus, current experimental data suggest
a complex cell-specific, context- and time-dependent role for the
CXCL12 system in cardiovascular biology and disease.
In this setting, ours is the first examination of the relationship of
plasma CXCL12 with prospective outcomes in humans. We found
that higher study-entry plasma CXCL12 related to incident MI and
death in a high-risk CKD population. The most straightforward inter-
pretation of our findings is that CXCL12 accelerates CHD and that
plasma levels provide a surrogate of CXCL12 actions in the vascula-
ture and for use in causal genomic interrogation (e.g. Mendelian ran-
domization) and therapeutic trials. However, several caveats require
consideration. First, plasma CXCL12 levels were correlated with
several cardio-metabolic risk factors, including measures of kidney
function. Although plasma CXCL12 predicted incident events even
in adjusted models, it is possible that residual confounding (by esti-
mates of renal-metabolic dysfunction and more precise measures
of cardiac injury) might have resulted in a spurious CXCL12 associ-
ation. Second, the association might be driven by reverse causation
whereby vascular disease leads to increasedCXCL12 secretion in re-
sponse to vascular injury, as suggested.14 Rodent studies using condi-
tional deletion of Cxcl12 coupled to specific dissection of its actions
via its two cognate receptors (Cxcr4 and Cxcr7) will help to clarify
the in vivo biology and causality. However, the possibility that
human mechanisms are distinct from rodent models needs consider-
ation given precedent for species difference in chemokine expres-
sion, splicing, and signalling.27
Human studies, employing a Mendelian randomization design,28,29
should provide insights into the causality of CXCL12 in human
disease. Such work is planned but is also challenging. To date, tool
SNPs in the CXCL12 region that relate to both plasma levels of
CXCL12 and CHD that could serve as instrumental variables are
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Table 2 Association of plasma CXCL12 with prevalent











Model 1 1.42 (1.32, 1.53) ,0.001 1.81 (1.56, 2.09) ,0.001
Model 2 1.36 (1.26, 1.46) ,0.001 1.66 (1.43, 1.93) ,0.001
Model 3 1.30 (1.20, 1.40) ,0.001 1.53 (1.31, 1.78) ,0.001
Model 4 1.23 (1.14, 1.33) ,0.001 1.38 (1.18, 1.62) ,0.001
Model 1: CXCL12 + demographic factors (age, sex, race).
Model 2: CXCL12 + demographic factors + traditional risk factors (diabetes,
hypertension, hypercholesterolaemia, tobacco use, body mass index).
Model 3: CXCL12 + demographic factors + traditional risk factors + plasma
inflammatory biomarkers (log transformed IL6, TNFa, and high-sensitivity
C-reactive protein).
Model 4: CXCL12 + demographic factors + traditional risk factors + plasma
inflammatory biomarkers + kidney function measures (CRIC-defined estimated
glomerular filtration rate21 and log-transformed urinary albumin:creatinine ratio).
aPrevalent CVD is defined as prior MI or coronary revascularization (n with any
CVD ¼ 1232; n without CVD ¼ 2455).
bFor one standard deviation increase in a plasma CXCL12.
cFor plasma CXCL12 levels above the median cut point value of 2.432 ng/mL.
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Table 3 Multivariable association of plasma CXCL12 with incident clinical events
Failure event (total n 5 3687) Hazard Ratio
a
(95% CI) P value Hazard ratio
b
(95% CI) P value
Probable Myocardial Infarction (n ¼ 174)
Model 1 1.37 (1.20, 1.56) ,0.001 2.01 (1.46, 2.75) ,0.001
Model 2 1.34 (1.17, 1.53) ,0.001 1.89 (1.38, 2.59) ,0.001
Model 3 1.26 (1.09, 1.45) 0.001 1.69 (1.22, 2.33) 0.001
Model 4 1.19 (1.03, 1.39) 0.02 1.52 (1.09, 2.13) 0.01
Death (n ¼ 355)
Model 1 1.36 (1.24, 1.49) ,0.001 1.90 (1.53, 2.37) ,0.001
Model 2 1.32 (1.20, 1.44) ,0.001 1.77 (1.42, 2.21) ,0.001
Model 3 1.20 (1.09, 1.33) ,0.001 1.51 (1.21, 1.88) ,0.001
Model 4 1.10 (0.99, 1.22) 0.09 1.28 (1.02, 1.61) 0.04
Any MI or death (n ¼ 485)
Model 1 1.37 (1.27, 1.49) ,0.001 1.90 (1.58, 2.30) ,0.001
Model 2 1.34 (1.23, 1.45) ,0.001 1.78 (1.47, 2.15) ,0.001
Model 3 1.23 (1.13, 1.34) ,0.001 1.53 (1.26, 1.85) ,0.001
Model 4 1.13 (1.03, 1.24) 0.01 1.30 (1.07, 1.59) 0.008
Model 1: CXCL12 + demographic factors (age, sex, race).
Model 2: CXCL12 + demographic factors + traditional risk factors (diabetes, hypertension, hypercholesterolaemia, tobacco use, body mass index).
Model 3: CXCL12 + demographic factors + traditional risk factors + plasma inflammatory biomarkers (log transformed IL6, TNFa, and high-sensitivity C-reactive protein).
Model 4: CXCL12 + demographic factors + traditional risk factors + plasma inflammatory biomarkers + kidney function measures (CRIC-defined estimated glomerular filtration
rate21 and log-transformed urinary albumin:creatinine ratio).
aFor one standard deviation increase in plasma CXCL12.
bFor plasma CXCL12 levels above the median cut point value of 2.432 ng/mL.










poorly characterized. Indeed, the SNPs associated with MI through
GWAS have only a minor impact on circulating CXCL12. Further,
tool variants that also lack impact on other biomarkers or causal
intermediates have not been defined. Last, circulating CXCL12
levels may be poor surrogates of cell-specific actions of CXCL12 iso-
forms in the vasculature rendering Mendelian randomization using
plasma CXCL12 assays non-informative of the underlying vascular
biology.
Our study has several strengths. The CRIC study is a unique, well-
phenotyped, prospective cohort study of CKD in participants at
high-risk for CVD. In CRIC, we can gain insight into how plasma
CXCL12 relates to multiple CVD and kidney biomarkers. Further,
we are able to simultaneously evaluate multiple cross-sectional
CVD phenotypes as well as adjudicated incident events. In future
work, repeated-measures biomarker data as well as whole-genome
data can be interrogated contributing greater insight into the relation
of CXCL12 and its signalling receptors with CHD in CRIC.
This work also has limitations. In CRIC, death events have not been
characterized as CV or non-CV in origin. However, for MI there were
careful review and adjudication by two blinded investigators ensuring
Figure 2 Multivariable-adjusted Kaplan–Meier plots for effect of plasma CXCL12 quartiles on incident events. Plasma CXCL12 level within the
lowest CXCL12 quartile (0.83–2.07) served as the referent value (hazard ¼ 1.0). The top panel presents Kaplan–Meier plots for models adjusted
for age, sex, and race. The bottom panel presents plots for models adjusted for age, sex, race, traditional cardiovascular risk factors, plasma inflam-
matorybiomarkers (IL6,TNFa, andhigh-sensitivityC-reactiveprotein), andkidney functionmeasures (CRIC-definedestimated glomerularfiltration
rate and urinary albumin:creatinine ratio).Tick marks on the x-axis indicate individual observations at corresponding levels of CXCL12. The solid
black line represents the multivariable-adjusted hazard of outcomes as a function of the CXCL12 level. Traditional risk factors include body
mass index and binary indicators for diabetes, hypertension, hypercholesterolaemia, and tobacco use.










high-quality data. Current assays of plasma CXCL12 may not capture
CXCL12 isoform activity in vasculature, butemergingdatadosuggest
that the alpha isoform, which circulates in plasma, is abundantly
expressed in macrophages and vascular cells.30 Residual confounding
and reverse causation are not excluded and, in the absence of add-
itional very large datasets with genomic data, plasma CXCL12 data,
and prospective events, human Mendelian randomization studies
are not yet feasible. Future analyses will also need to address
whether CXCL12 levels predict CVD after controlling for circulating
natriuretic peptides and high-sensitivity cardiac troponins, powerful
predictors of CVD in CKD. Our exploration of performance in risk
prediction suggests that plasma CXCL12 improves prediction of MI
and death when added to traditional risk factors and eGFR and also
enhances modestly risk reclassification in patients with CKD.
However, our goal in this work was not to suggest development
plasma CXCL12 as a new biomarker of CVD risk for use clinically.
Additional large studies are needed in diverse populations to define
clinical utility in risk prediction using both plasma CXCL12 and
genetic data from the CXCL12 region in the context of evolving
evidence for CXCL12 in CVD.
In conclusion, we demonstrate that in CKD, higher levels of
plasma CXCL12 were associated with known cardiovascular risk
factors and prevalent CVD and also predicted incident MI and
death even after adjustment for traditional risk factors and mea-
sures of kidney dysfunction. While these findings suggest that
higher plasma CXCL12 may be atherogenic, further mechanistic,
genomic and interventional studies are required to establish if
plasma CXCL12 levels reflect causal actions at the vessel wall and
to determine whether CXCL12 leads to increased risk of MI and
CVD in humans.
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Supplementary material is available at European Heart Journal online.
Acknowledgement
We acknowledge the commitment of the participants, investigators
and staff of the CRIC study.
Funding
This work was supported under a cooperative agreement from National
Institute of Diabetes and Digestive and Kidney Diseases (U01DK060990,
U01DK060984, U01DK061022, U01DK061021, U01DK061028,
U01DK060980, U01DK060963, and U01DK060902). This work was
supported in part by: the University of Pennsylvania (CTRC CTSA UL1
RR-024134), Johns Hopkins University (UL1 RR-025005), University of
Maryland (GCRC M01 RR-16500), Clinical and Translational Science
Collaborative of Cleveland (UL1TR000439) from the National Center
for Advancing Translational Sciences (NCATS) component of the Na-
tional Institutes of Health and NIH roadmap for Medical Research, Mich-
igan Institute for Clinical and Health Research (MICHR) (UL1RR024986),
University of Illinois at Chicago (CTSA UL1RR029879), The Clinical and
Translational Research, Education, and Commercialization Project
(CTRECP), Kaiser NIH/NCRR (UCSF-CTSI UL1 RR-024131). This
work was supported directly by R01-DK071224 (to M.P.R.). N.N.M. is
supported by National Institutes of Health Intramural Award
HL-Z0000. M.J.F. is supported by a Department of Veterans Affairs
Health Services Research and Development Service Award. H.F. is sup-
ported by K24-DK002651. A.F. is supported by R01-HL107196. M.P.R.
is also supported by K24-HL107643, R01-DK090505, U01-HL108636,
and R01-HL113147.
Conflict of interest: none declared.
Appendix: Chronic Renal
Insufficiency Cohort (CRIC) study
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Table 4 Change in the area under the curve for probable myocardial infarction, death and the composite of myocardial
infarction or death with addition of (A) CXCL12 dataa and (B) estimated glomerular filtration rate data
(A) Add CXCL12 to model
ROC AUC in Model 2 ROC AUC in Model 2 + eGFR
Without CXCL12 With CXCL12 P-value Without CXCL12 With CXCL12 P-value
Probable MI 0.664 0.685 0.003 0.690 0.698 0.023
Death 0.674 0.695 ,0.001 0.723 0.727 0.049
MI or death 0.660 0.680 ,0.001 0.703 0.707 0.057
(B) Add eGFR to model
ROC AUC in Model 2 ROC AUC in Model 2 + CXCL12
Without eGFR With eGFR P-value Without eGFR With eGFR P-value
Probable MI 0.664 0.690 0.002 0.685 0.698 0.017
Death 0.674 0.723 ,0.001 0.695 0.727 ,0.001
MI or death 0.660 0.703 ,0.001 0.680 0.707 ,0.001
aStandardized plasma CXCL12 values.
Model 2: CXCL12 + demographic factors + traditional risk factors (diabetes, hypertension, hypercholesterolaemia, tobacco use, body mass index).
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